Fig. 3From: Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosisLy-6Chi cells are homogeneously represented in EAE-Vehicle and EAE-FTY720 mice before treatment. A Representative plots of Ly-6Chi cells from EAE mice that will be treated with vehicle (left panel) or fingolimod (right panel). B The abundance of Ly-6Chi cells relative to the total cells or to the myeloid component at disease onset was similar between both experimental study groups prior to the beginning of treatment. C Representative histograms from the main phenotypic markers of circulating Ly-6Chi cells at disease onset. D, E The MFI of the different markers of Ly-6Chi cells did not differ prior to onset of treatmentBack to article page